Heart failure patients get continued access to promising oral treatment
NCT ID NCT07436689
First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times
Summary
This study offers continued access to an oral medication called levosimendan for people with pulmonary hypertension (high blood pressure in the lungs) and a type of heart failure where the heart pumps normally but is stiff. About 800 participants who completed a previous levosimendan study can join. The main goal is to track safety over the long term.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY HYPERTENSION ASSOCIATED WITH HFPEF are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tenax Investigational Site
Chicago, Illinois, 60611, United States
-
Tenax Investigational Site
Minneapolis, Minnesota, 55455, United States
-
Tenax Investigational Site
Rochester, Minnesota, 55905, United States
-
Tenax Investigational Site
St Louis, Missouri, 63136, United States
-
Tenax Investigational Site
Omaha, Nebraska, 68198, United States
-
Tenax Investigational Site
Charleston, South Carolina, 29425, United States
-
Tenax Investigational Site
Madison, Wisconsin, 53792, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.